145 related articles for article (PubMed ID: 19888514)
1. Binding between heparin and the integrin VLA-4.
Schlesinger M; Simonis D; Schmitz P; Fritzsche J; Bendas G
Thromb Haemost; 2009 Nov; 102(5):816-22. PubMed ID: 19888514
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Schlesinger M; Schmitz P; Zeisig R; Naggi A; Torri G; Casu B; Bendas G
Thromb Res; 2012 May; 129(5):603-10. PubMed ID: 22099706
[TBL] [Abstract][Full Text] [Related]
3. Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4.
Schmitz P; Gerber U; Schütze N; Jüngel E; Blaheta R; Naggi A; Torri G; Bendas G
Thromb Haemost; 2013 Nov; 110(5):1046-54. PubMed ID: 24009013
[TBL] [Abstract][Full Text] [Related]
4. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
Schlesinger M; Roblek M; Ortmann K; Naggi A; Torri G; Borsig L; Bendas G
Thromb Res; 2014 May; 133(5):855-62. PubMed ID: 24636486
[TBL] [Abstract][Full Text] [Related]
5. Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches.
Fritzsche J; Simonis D; Bendas G
Thromb Haemost; 2008 Dec; 100(6):1166-75. PubMed ID: 19132244
[TBL] [Abstract][Full Text] [Related]
6. Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
Gerber U; Hoß SG; Shteingauz A; Jüngel E; Jakubzig B; Ilan N; Blaheta R; Schlesinger M; Vlodavsky I; Bendas G
Semin Thromb Hemost; 2015 Mar; 41(2):244-54. PubMed ID: 25682080
[TBL] [Abstract][Full Text] [Related]
7. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers.
Klemke M; Weschenfelder T; Konstandin MH; Samstag Y
J Cell Physiol; 2007 Aug; 212(2):368-74. PubMed ID: 17352405
[TBL] [Abstract][Full Text] [Related]
8. Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
Stevenson JL; Choi SH; Varki A
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7003-11. PubMed ID: 16203794
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Tumor-Host Cell Interactions Using Synthetic Heparin Mimetics.
Gockel LM; Heyes M; Li H; Al Nahain A; Gorzelanny C; Schlesinger M; Holdenrieder S; Li JP; Ferro V; Bendas G
ACS Appl Mater Interfaces; 2021 Feb; 13(6):7080-7093. PubMed ID: 33533245
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin inhibits sickle erythrocyte adhesion to VCAM-1 through VLA-4 blockade in a standardized microfluidic flow adhesion assay.
Lancelot M; White J; Sarnaik S; Hines P
Br J Haematol; 2017 Aug; 178(3):479-481. PubMed ID: 27341635
[No Abstract] [Full Text] [Related]
11. Blocking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins.
Schlesinger M; Naggi A; Torri G; Zeisig R; Alexander M; Schmitz P; Casu B; Bendas G
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):448-50. PubMed ID: 20557840
[No Abstract] [Full Text] [Related]
12. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model.
Sudha T; Phillips P; Kanaan C; Linhardt RJ; Borsig L; Mousa SA
Clin Exp Metastasis; 2012 Jun; 29(5):431-9. PubMed ID: 22415710
[TBL] [Abstract][Full Text] [Related]
13. Integrin VLA-4 enhances sialyl-Lewisx/a-negative melanoma adhesion to and extravasation through the endothelium under low flow conditions.
Liang S; Dong C
Am J Physiol Cell Physiol; 2008 Sep; 295(3):C701-7. PubMed ID: 18632734
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-α enhanced fusions between oral squamous cell carcinoma cells and endothelial cells via VCAM-1/VLA-4 pathway.
Song K; Zhu F; Zhang HZ; Shang ZJ
Exp Cell Res; 2012 Aug; 318(14):1707-15. PubMed ID: 22664325
[TBL] [Abstract][Full Text] [Related]
15. The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.
Gockel LM; Ponert JM; Schwarz S; Schlesinger M; Bendas G
Molecules; 2018 Oct; 23(11):. PubMed ID: 30356007
[TBL] [Abstract][Full Text] [Related]
16. VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow.
White J; Krishnamoorthy S; Gupta D; Lancelot M; Moore N; Sarnaik S; Hobbs WE; Light DR; Hines P
Br J Haematol; 2016 Sep; 174(6):970-82. PubMed ID: 27291690
[TBL] [Abstract][Full Text] [Related]
17. Nanoscale Tuning of VCAM-1 Determines VLA-4-Dependent Melanoma Cell Plasticity on RGD Motifs.
Amschler K; Kossmann E; Erpenbeck L; Kruss S; Schill T; Schön M; Möckel SMC; Spatz JP; Schön MP
Mol Cancer Res; 2018 Mar; 16(3):528-542. PubMed ID: 29222169
[TBL] [Abstract][Full Text] [Related]
18. Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis.
Schlesinger M; Bendas G
Cancer Metastasis Rev; 2015 Dec; 34(4):575-91. PubMed ID: 25564456
[TBL] [Abstract][Full Text] [Related]
19. Kinetic analysis of heparin and glucan sulfates binding to P-selectin and its impact on the general understanding of selectin inhibition.
Simonis D; Fritzsche J; Alban S; Bendas G
Biochemistry; 2007 May; 46(20):6156-64. PubMed ID: 17458940
[TBL] [Abstract][Full Text] [Related]
20. Relationship between molecular and cellular dissociation rates for VLA-4/VCAM-1 interaction in the absence of shear stress.
Zwartz G; Chigaev A; Foutz T; Larson RS; Posner R; Sklar LA
Biophys J; 2004 Feb; 86(2):1243-52. PubMed ID: 14747358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
